within Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01A_AnteriorPituitaryLobeHormonesAndAnalogues.H01AC07_Somapacitan;

model Somapacitan
  extends Pharmacolibrary.Drugs.ATC.H.H01AC07;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>H01AC07</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Somapacitan is a long-acting, reversible albumin-binding human growth hormone analog used for the treatment of growth hormone deficiency (GHD) in adults and children. It is administered once weekly and is approved by regulatory agencies such as the FDA and EMA.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from population PK analysis in adult patients with growth hormone deficiency, both sexes, generally healthy with GHD condition.</p><h4>References</h4><ol><li><p>Helleberg, H, et al., &amp; Bjelke, M (2022). Structure identification of circulating metabolites from somapacitan, a long-acting growth hormone derivative, and pharmacokinetics after single and multiple subcutaneous dosing in rats. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 168 106032–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ejps.2021.106032&quot;>10.1016/j.ejps.2021.106032</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34610450/&quot;>https://pubmed.ncbi.nlm.nih.gov/34610450</a></p></li><li><p>Bentz Damholt, B, et al., &amp; Højby Rasmussen, M (2021). Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials. <i>Clinical pharmacokinetics</i> 60(8) 1015–1027. DOI:<a href=&quot;https://doi.org/10.1007/s40262-021-00990-7&quot;>10.1007/s40262-021-00990-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33754315/&quot;>https://pubmed.ncbi.nlm.nih.gov/33754315</a></p></li><li><p>Helleberg, H, et al., &amp; Rasmussen, MH (2021). Absorption, metabolism and excretion of once-weekly somapacitan, a long-acting growth hormone derivative, after single subcutaneous dosing in human subjects. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 167 106030–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ejps.2021.106030&quot;>10.1016/j.ejps.2021.106030</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34601071/&quot;>https://pubmed.ncbi.nlm.nih.gov/34601071</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Somapacitan;
